Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:17:55.824Z.
Calculation as of: 2026-10-06T16:17:55.824Z.
Quote observation: 2026-10-06T16:14:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 71eb9fd1524c6a7909807b3579e07ffedc3dd33f5194760f8552a0f1956527a0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
ENDRA Life Sciences Inc.
Market Cap
$7.96M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| ENDRA Life Sciences Inc. (NDRA) | $7.96M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.86M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.05M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.11M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.34M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.62M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.53M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.29M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.36M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
